Early clinical researchPhase INCT07783477
ARMADA — armored CAR-T (DLL3+ cancers, phase I)
Multiple / solid tumors
Phase I armored CAR-T; recruiting. Solid-tumor translation early — not GI standard.
Registry checked: 2026-10-29
Research area · Emerging treatment technologies
Armored CAR-T — solid tumors
Araştırma alanı dosyası (tek çalışma değil): zırhlı / sitokin zırhlı CAR-T (katı tümörler)
- Record type
- Treatment-technology research area (not a single NCT)
- Evidence level
- Mostly early clinical (phase I) in solid tumors. Hematologic CAR-T success does not automatically transfer.
- Linked records
- 1
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
- Scope
- Multiple / solid tumors — Araştırma alanı — alt kartlarda hastalık tipine göre
- How it works
- Patient T cells are engineered to recognize cancer. ‘Armoring’ can add signals such as IL-18 so cells work better in immunosuppressive solid-tumor microenvironments.
- Translational distance
- Solid-tumor translation is early; toxicity, target choice, and manufacturing are critical. Not a surgical-oncology standard.
For patients
What is being studied? Immune cells can be engineered in the lab to recognize cancer and returned to the patient. In solid tumors this approach is still early research.
Why promising? Hypothesis of improving T-cell fitness inside immunosuppressive solid-tumor environments.
What is not proven? Broad solid-tumor efficacy; routine GI surgical-oncology use; long-term safety.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
Site priority: high. Example: ARMADA NCT07783477 (DLL3+; phase I). No automatic generalization to GI surgical indications.
Cancer / population: Multiple / solid tumors — Araştırma alanı — alt kartlarda hastalık tipine göre
Intervention: Genetik olarak yeniden programlanmış T hücreleri ± IL-18 vb. ‘zırh’ sinyalleri
Primary endpoint: Alan düzeyinde tek primer sonlanım yok
Limitations: Erken faz; hastalık seçimi (DLL3+ nöroendokrin/SCLC vb.) dar olabilir.
Real studies in this area
Each card is a separate clinical or discovery record — not one NCT.